Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics director David L. Barker received a new stock option grant as part of his compensation. The award covers 9,149 shares of common stock at an exercise price of $1.19 per share, with no cash paid at grant.
The option vests in equal monthly installments over the 12 months following the grant date and will in any case be fully vested by the date of the company's next annual stockholder meeting, as long as Barker maintains continuous service. The award will also vest in full upon a qualifying Change of Control under the company's 2018 equity incentive plan.
Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders and reported voting results on three proposals. As of the March 19, 2026 record date, 11,091,615 common shares were outstanding and entitled to vote, with 4,225,995 shares represented, or about 38.1% participation.
Stockholders elected Class II directors Albert Luderer, Ph.D. and Kristiina Vuori, M.D., Ph.D., each to serve until the 2029 annual meeting or earlier departure. They also approved, on an advisory basis, compensation of named executive officers and ratified BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2026.
Bionano Genomics, Inc. reported Q1 2026 revenue of $6.7M, up 4% year over year, driven by higher instrument, consumable, and service revenue, partly offset by lower software sales. Product revenue was $6.1M and service and other revenue $0.6M.
The company’s net loss widened to $8.3M from $3.1M, with operating cash outflows of $5.7M. As of March 31, 2026, Bionano held $3.4M in cash and cash equivalents, $11.0M in short-term investments, and $10.3M in restricted cash and investments.
Management states there is substantial doubt about the company’s ability to continue as a going concern within 12 months without significant new capital. Bionano has $10.3M of Senior Secured Convertible Debentures outstanding and is relying on additional equity or debt financing to fund operations beyond the near term.
Bionano Genomics reported Q1 2026 revenue of $6.7 million, up 4% from $6.5 million a year earlier, with improving margins but a wider loss. Gross margin reached 49%, compared to 46% in Q1 2025, supported by higher consumables use and services.
Consumables revenue was $3.9 million, up 20%, and the company sold 8,178 nanochannel array flow cells, a 17% increase. Operating expenses declined 2% to $11.1 million, but net loss widened to $8.3 million from $3.1 million, partly reflecting weaker other income.
Bionano highlighted reimbursement tailwinds, including a new Category I CPT code 81354 effective January 1, 2026 and a 47% payment increase for CPT code 81195 to $1,853.22. The company guided Q2 2026 revenue to $7.5–$7.8 million and full-year 2026 revenue to $30–$33 million, and reiterated expectations to retire its secured convertible debt.
Bionano Genomics, Inc. filed a shelf registration statement to offer and sell up to $400,000,000 of common stock, preferred stock, debt securities, warrants and/or units. The prospectus is a general shelf: specific terms, prices and amounts for any offering will be provided in prospectus supplements.
The filing replaces a prior registration and permits issuance of securities covered by the earlier statement until the earlier of effectiveness or November 6, 2026. Net proceeds are intended for general corporate purposes, including working capital, R&D, repayment of indebtedness and capital expenditures.
Bionano Genomics, Inc. removed R. Erik Holmlin, Ph.D. as president and chief executive officer effective May 5, 2026, and he also resigned from the board. He will receive severance under his employment agreement and is expected to serve as an advisor/consultant during the transition.
The board appointed chairman Albert A. Luderer, Ph.D. as interim chief executive officer and interim principal financial officer, while he continues as board chair. Under an offer letter dated May 6, 2026, he will receive a $600,000 annual base salary, up to a $400,000 pro-rated 2026 incentive bonus, and a $4,000 monthly housing and travel stipend.
Christopher J. Twomey was named Lead Independent Director and joined the compensation committee. The company plans to conduct a search for a permanent CEO and stated it anticipates a seamless leadership transition without business disruption.
Bionano Genomics, Inc. is calling its 2026 Annual Meeting of Stockholders for May 14, 2026 at 10:00 a.m. Pacific Time, to be held exclusively online via live audio webcast at www.proxydocs.com/BNGO.
Stockholders will vote on electing two Class II directors to serve until the 2029 annual meeting, an advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board recommends voting “For” all three proposals. Stockholders of record as of March 19, 2026, when 11,091,615 shares of common stock were outstanding, are entitled to vote.
Bionano Genomics provides genome analysis solutions centered on optical genome mapping (OGM), nucleic acid purification, diagnostic services and VIA software. It focuses on structural variant detection in constitutional disease, cancer and cell and gene therapy research.
The company flags substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flows and a need for significant additional capital, with potential outcomes including curtailing operations or liquidation. As of June 30, 2025, non‑affiliate equity market value was about $12.2 million, and as of March 19, 2026 there were 11,092,000 common shares outstanding.
Bionano reports an installed base of 387 OGM systems at December 31, 2025 and annual flowcell sales of 30,171, slightly below 2024. It highlights recent milestones including new VIA and Solve software advances, deployment of the Stratys system, and establishment of Category I CPT codes and Medicare payment determinations for OGM in hematologic malignancies and constitutional genetic disorders.
Bionano Genomics reported Q4 2025 revenue of $8.0M, down 3% from Q4 2024, with gross margin improving to 43%. For full-year 2025, revenue was $28.5M, a 7% decline from 2024 as instrument and discontinued clinical services revenue fell, partly offset by higher consumables and software revenue.
Full-year gross margin rose sharply to 46% from 1%, and operating expenses dropped 55% to $46.5M, reducing net loss to $26.4M from $112.0M. The company ended 2025 with $29.6M in cash, equivalents, investments and restricted short-term investments and guided 2026 revenue to $30–33M, with Q1 2026 guidance of $6.5–6.7M.